CGRP-REZEPTORANTAGONISTEN

European patent · EP2552906 · In force

Register entry

Publication number
EP2552906
Application number
EP11710087
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 11, 2011
Published
Feb 6, 2013
Granted
Jan 6, 2016
Protection ends at the latest
Mar 10, 2031
Next annual fee due
Mar 31, 2027
IPC classes
C07D 401/14 (2006.01)
A61K 31/496 (2006.01)
A61P 29/00 (2006.01)
Priority
US 319015 P 30.03.2010
PCT application
PCT/US2011/028168 11.03.2011
PCT publication
WO2011/123232 06.10.2011
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  4. Apr 1, 2023

    Change

    Published in Swissreg on 01.04.2023

  5. Feb 2, 2016

    Agent entered

    Representative
    Marks & Clerk (Luxembourg) LLP, Dreikönigstrasse 31a, 8002 Zürich

    Published in Swissreg on 02.02.2016

  6. Jan 6, 2016

    Granted

    Published in Swissreg on 06.01.2016

Parties

Holder

Bristol-Myers Squibb Company

Route 206 and Province Line Road, Princeton, NJ 08543, US

Agent

Marks & Clerk (Luxembourg) LLP

Dreikönigstrasse 31a, 8002 Zürich

Inventor

CHATURVEDULA, Prasad V.

Wallingford, Connecticut 06492, US

DUBOWCHIK, Gene M.

Wallingford, Connecticut 06492, US

MACOR, John E.

Wallingford, Connecticut 06492, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.